Change in the Composition
of the Intrasense Board of Directors

Montpellier, France, May 23, 2025, 6:00pm. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), the
F renc h expert in AI- enhanc ed medic al imaging s olutions that fac ilitate and s ec ure diagnos is , dec is ion-
making and therape utic follow- up (the “Company”), announces a change in the composition of its
Board of Directors

At its meeting on May 21, 2025, the Board of Directors of Intrasense noted the resignation of Mrs.
Michèle Lesieur from her position as Director of the Company, effective May 23, 2025, and has co-
opted Mr. Steven F. Tolle as a Director, effective May 23, 2025. Mr Steven F. Tolle has been co-opted
for the remainder of Mrs. Michèle Lesieur's term of office, i.e. until the General Meeting of shareholders
called in 2029 to approve the financial statements for the year ending December 31, 2028, and this co-
optation will be submitted for ratification by the Company’s General Meeting of shareholders to be held
on June 25, 2025.

The Board of Directors warmly thanks Mrs. Michèle Lesieur for her valuable and dedicated contribution
and extends a warm welcome to Mr. Steven F. Tolle. The Board looks forward to this future
collaboration.

Steven F. Tolle brings over 30 years of experience in the healthcare
sector, spanning medical technologies, artificial intelligence, medical
devices, and digital health services.

He currently serves as Chief Product & Technology Officer at IgniteData.
He was formerly General Partner at HLM Venture Partners, a venture
capital fund specializing in healthcare. At IBM Watson Health, he led global
strategic development for medical imaging, including a major partnership
with Guerbet. He also held executive positions at Merge Healthcare,
where he led a turnaround strategy prior to its acquisition by IBM for $1
billion.

Mr. Tolle advised Guerbet's strategic committee on AI and technology trends between 2020 and 2023.
His professional background includes experience in both the United States and Europe. Mr. Tolle
graduated from Washington University in St. Louis.


Following this change, the Intrasense Board of Directors now consists of six members:
• F ranç ois Nic olas , Chairman of the Board
• C harlotte B amière, Director
• J érôme E s tampes , Director
• Anne Larpin, Independent Director
• P atric e R ullier, Independent Director
• S teven F . T olle, Independent Director




Press release 1/2
About Intrasense
A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group,
Intrasense designs medical imaging software solutions natively enriched by artificial intelligence
algorithms.
Myrian®, an advanced radiology visualization platform featuring cutting-edge clinical tools, optimizes
and simplifies the interpretation of all types of images. DUOnco™, a range of expert AI algorithms for
oncology, offers an AI for the detection of focal liver lesions and the first AI dedicated to CE-marked
bone lesions. Liflow®, a dedicated oncology monitoring solution integrating multi-organ AIs, optimizes
the longitudinal monitoring of cancer patients.
By combining clinical expertise and operational performance, Intrasense provides healthcare
professionals with high medical value tools, facilitating analysis, diagnosis and patient management.
More information on www.intrasense.fr


Contacts
INTRASENSE SEITOSEI.ACTIFIN
Communication officer Analyst & Investor Relations
Salomé Sylvestre Foucauld Charavay
Phone : +33 4 67 13 01 30 Phone : +33 6 37 83 33 19
investisseurs@intrasense.fr intrasense@seitosei-actifin.com

Press Relations
Isabelle Dray
Phone : +33 1 56 88 11 29
isabelle.dray@seitosei-actifin.com




Press release 2/2